Advances in High-Precision Radiotherapy Treatments Unveiled by Varian at ESTRO 2006, Leipzig, October 8-11 | Varian

Advances in High-Precision Radiotherapy Treatments Unveiled by Varian at ESTRO 2006, Leipzig, October 8-11

Zug, Switzerland, October 5th 2006 – Varian Medical Systems, world leader in radiotherapy solutions for treating cancer, is exhibiting the latest breakthroughs in treatment technology at the 2006 European Society of Therapeutic Radiation Oncologists (ESTRO) meeting in Leipzig, Germany. On display will be product innovations which enable advanced radiotherapy treatments such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT) and stereotactic radiosurgery (SRS) to be delivered more rapidly, with more automation and with greater comfort for the patient.

The comprehensive ARIA™ oncology information and image management system, already in clinical use at a number of centers in the US and Europe, will be demonstrated on the Varian booth (37). This system combines all patient records into one powerful solution, making all administrative, clinical and financial information readily available to cancer care professionals when and where it is needed. An oncology-specific Electronic Medical Record (EMR), ARIA works seamlessly with Varian’s Eclipse™ treatment planning system.

The latest version of Eclipse, the fastest, most comprehensive and most versatile treatment planning software on the market, is also on display. Among this version’s additional features is fast 3D image registration, enabling newly-acquired 3D kV Cone Beam CT images to be matched to the planning CT image in seconds.

Along with the market-leading On Board Imager® device for clinically-practical image guided radiotherapy (IGRT), Varian will also be demonstrating its Trilogy™ and Clinac® linear accelerators, its Acuity imaging device for planning and simulating treatments and its full range of planning and delivery tools for brachytherapy.

Varian will also feature Dynamic Adaptive Radiotherapy (DART), the next stage in personalized cancer care and the natural successor to IGRT. DART offers an automated and integrated way of adapting radiotherapy treatment plans based on the better imaging afforded by IGRT and Varian is pioneering advances in this area.

“At ESTRO, Varian is focusing on the clinical utilisation of our recent innovations and taking a look at what is just around the corner,‿ says Rolf Staehelin, head of Varian’s Oncology Systems marketing organisation in Europe. “We are demonstrating how Varian continues to be at the forefront of advances in radiotherapy, with a clear technology and market lead in clinically-practical image-guided radiotherapy, intensity-modulated radiotherapy and stereotactic radiosurgery.‿

Varian is hosting an Emerging Technologies satellite symposium from 12.30pm-2pm on Tuesday October 10th at Multipurpose Area 1 & 2, Level 0, of the Messe Leipzig complex. Papers will be presented by speakers from a number of leading academic institutions, including the Clatterbridge Centre for Oncology in the Wirral, UK, Rigshospitalet in Copenhagen, Denmark and Clinique Sainte Catherine in Avignon, France. The session will be chaired by Professor Cai Grau of Aarhus University Hospital, Denmark. In addition, a Varian Users Meeting takes place at the Westin Hotel in Leipzig on Saturday October 7th.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068,

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of medical technology for treating cancer with radiotherapy and neurological conditions with radiosurgery. The company is also a premier supplier of X-ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,600 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. In Europe, the company operates manufacturing and engineering centers in Baden (Switzerland), Crawley (England), Haan (Germany), Helsinki (Finland) and Toulouse (France) and has headquarters for Europe, Middle East, India and Africa (EMEA) based in Zug, Switzerland.Additional information is available on the company's web site at

Forward Looking Statements
Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "expect," constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the Company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the U.S. Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise. Furthermore, notwithstanding any specific events announced in this press release, the Company's quarterly and annual financial results are subject to such risks and uncertainties described in the Company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the U.S. Securities and Exchange Commission and actual results may differ materially from those anticipated.